Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma
Abstract Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed malignancies worldwide with poor prognosis and tends to be hypervascular. Aberrant expression of the vascular endothelial growth factor 2 (VEGFR‐2) has been implicated in the progression of HCC and represents a valid targe...
Main Authors: | Chaoxu Yang, Shukui Qin |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-09-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.1664 |
Similar Items
-
Progress in the treatment of solid tumors with apatinib: a systematic review
by: Zhao D, et al.
Published: (2018-07-01) -
Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
by: Jingjing Ge, et al.
Published: (2021-02-01) -
Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling
by: Cai X, et al.
Published: (2020-10-01) -
Research Progress of Combination Therapy of Apatinib on Tumor
by: WU Shan, et al.
Published: (2019-03-01) -
Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma
by: Fang S, et al.
Published: (2017-01-01)